0000-0002-1681-2842 Employment
-
Alnylam Pharmaceuticals Inc
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (15)
- Mechanistic Insights into Hybridization-Based Off-Target Activity of GalNAc-siRNA Conjugates Save
- Towards in vitro models for reducing or replacing the use of animals in drug testing Save
- Shorter Is Better: The α-(<scp>l</scp>)-Threofuranosyl Nucleic Acid Modification Improves Stability, Potency, Safety, and Ago2 Binding and Mitigates Off-Target Effects of Small Interfering RNAs Save
- RNAi-mediated rheostat for dynamic control of AAV-delivered transgenes Save
- Role of a “Magic” Methyl: 2′-Deoxy-2′-α-F-2′-β-C-methyl Pyrimidine Nucleotides Modulate RNA Interference Activity through Synergy with 5′-Phosphate Mimics and Mitigation of Off-Target Effects Save
- From bench to bedside: Improving the clinical safety of GalNAc–siRNA conjugates using seed-pairing destabilization Save
- Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates Save
- The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of GalNAc–Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human Save
- Impact of Serum Proteins on the Uptake and RNAi Activity of GalNAc-Conjugated siRNAs. Save
- Leveraging microphysiological systems to address challenges encountered during development of oligonucleotide therapeutics Save